Study of TYRA-300 for bladder cancer that has not spread into muscle
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You need to have low-grade bladder cancer (Ta or T1) that has not spread into the muscle.
- You must have a specific change in the FGFR3 gene, which your doctor can test for.
- You need to have at least one of these: cancer that came back within a year, a single tumor larger than 3 cm, multiple tumors, or T1 low-grade cancer.
- You must not have had certain bladder treatments recently (BCG within 3 months, chemo in the bladder within 8 weeks).
- You need to be generally healthy with adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill, TYRA-430, for people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have certain genetic changes (in the FGF/FGFR pathways). It aims to see if the drug is safe and if it can shrink or slow the growth of the cancer.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial tests a new targeted therapy pill, dabogratinib, for people with low-grade upper tract urothelial carcinoma (a type of cancer in the tubes that carry urine from kidneys to bladder). It may be an option if you have tumor tissue left after a biopsy and haven't had certain prior treatments.
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
This trial tests a new drug, RAG-01, for people with a type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC) that has come back after BCG therapy. The drug is given through a catheter into the bladder, and the study aims to see if it can help control the cancer.
Hear when a new FGFR Gene Alterations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.